- Home
- ISPR vs ADAG Comparison
ISPR vs ADAG Comparison
Compare ISPR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | ADAG |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 146.3M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ISPR | ADAG |
|---|---|---|
| Price | $1.86 | $3.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.50 | ★ $8.25 |
| AVG Volume (30 Days) | 127.9K | ★ 304.7K |
| Earning Date | 05-11-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,494,304.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.31 | $20.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $1.36 |
| 52 Week High | $3.87 | $4.75 |
Technical Indicators
Market Signals| Indicator | ISPR | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 51.72 |
| Support Level | $1.64 | $1.69 |
| Resistance Level | $2.04 | $4.66 |
| Average True Range (ATR) | 0.17 | 0.48 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 55.28 | 28.28 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.